# Eupraxia Pharmaceuticals Inc. (EPRX)

> Source: Nexqual · https://nexqual.com/EPRX · data as of 2026-10-29 20:00 UTC · cite as "Nexqual, Eupraxia Pharmaceuticals Inc. (EPRX), nexqual.com/EPRX" · informational, not investment advice.

**Price:** USD 7.25 (-1.76% on the day) · last close of Oct 29, 2026; US market closed, not a live price. Prev close 7.38 · day 7.1–7.51 · 52w 5.25–9.32 · market cap $479M · NMS

## Key facts
- Analysts: Buy (mean 2.00 on a 1–5 scale) (12 analysts), mean target USD 16.61 (range 11–25).
- Total return with dividends: 1Y +38.5% vs S&P 500 +14.8%; 5Y +145.8% vs S&P 500 +79.1%.
- Next earnings: 2026-11-03 (date not yet confirmed by the company), EPS estimate USD -0.26, revenue estimate $0K. All companies reporting that day: https://nexqual.com/earnings/2026-11-03
- Dividend: EPRX paid no cash dividend in the last five years.
- Short interest: 6,538,961 shares (as of 2026-10-15), 7.2 days to cover.

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 12 analysts; mean target USD 16.61 (low 11, high 25).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-01 | HC Wainwright & Co. | Reiterated | Buy | $11 |
| 2026-09-24 | Wedbush | Initiated | Outperform | $17 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-30) | 5Y (from 2024-04-01) |
|---|---|---|
| Total return | +38.5% | +145.8% |
| S&P 500 (SPY) | +14.8% | +79.1% |
| Per year | +38.7% | +41.7% |
| Volatility (annualized) | 66.5% | 49.7% |
| Max drawdown | -35.9% (Feb 2026→Jul 2026) | -35.4% (Jan 2026→Jul 2026) |

## Dividends
EPRX paid no cash dividend in the last five years.

## Short interest
6,538,961 shares sold short, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 7,582,355 shares (-13.8%). Days to cover: 7.2 (short shares ÷ average daily volume).

## Peers (Biotechnology)
ORKA (Oruka Therapeutics, Inc.) USD 96.65 +0.71% · LGND (Ligand Pharmaceuticals Incorpor) USD 317.33 -0.45% · IOVA (Iovance Biotherapeutics, Inc.) USD 9.56 -35.45% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.39 -1.14% · AXSM (Axsome Therapeutics, Inc.) USD 143.45 -0.04% · ABVX (Abivax SA) USD 89.06 -0.87%

## More
Full page: https://nexqual.com/EPRX · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.26 | $-0.24 | −$0.01 | $0 | 8 |
| Next quarter (ends 2026-12-31) | $-0.27 | $-0.25 | −$0.02 | $0 | 8 |
| Current fiscal year (ends 2026-12-31) | $-0.98 | $-0.97 | −$0.01 | $0 | 8 |
| Next fiscal year (ends 2027-12-31) | $-1.04 | $-0.90 | −$0.14 | $709,820 | 10 |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$0.23 | −$0.23 | In line | — |
| — | Quarter ended Dec 31, 2025 | −$0.37 | −$0.16 | Miss −131.3% | — |
| — | Quarter ended Sep 30, 2025 | −$0.19 | −$0.19 | In line | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).